Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-01-19-Speech-3-223-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-01-19"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20110119.20.3-223-000"2
lpv:hasSubsequent	lp_eu:2011-01-19-Speech-3-224-0002
lpv:speaker	lp:Filip Kaczmarek2
lpv:spokenAs	member; DEVE (2009-07-16--2012-01-18)3 member_of_the_bureau; EPP (2009-07-24--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; AGRI (2009-07-16--2012-01-18)3 member; Delegation for relations with the Pan-African Parliament (2009-09-16--2014-06-30)3 unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3 substitute; Delegation for relations with Israel (2009-09-16--2014-06-30)3
lpv:translated text	"I voted in favour of adopting the Grossetête report for several key reasons. The directive on the application of patients’ rights in cross-border healthcare has many positive features. It abolishes barriers to treatment, ensures equal access for all to healthcare throughout the EU, marks an end to discrimination against patients, introduces the mutual recognition of prescriptions, reduces waiting times for doctors’ appointments and removes the need for additional insurance abroad. The fact that the directive introduces wide-ranging access to medical care for individuals suffering from rare diseases, and higher rates of reimbursement for disabled people, are additional points in its favour. The directive works to prevent medical tourism by stipulating that the costs of treatment will be reimbursed up to the level guaranteed in the insuring country, and if the costs actually incurred are lower than this, they will be reimbursed in full. The issue of authorisation has given rise to much debate. The prior agreement of the national health fund will only be required in the case of hospital treatment or expensive medical procedures, and it will not be required for any other form of treatment, provided that they are covered by what is known as the basket of guaranteed services. If a Member State has not authorised patients to receive specialist treatment at national level, the directive does not create any new right for patients to receive such treatment abroad or for the costs of treatment to be reimbursed. A key exception is the case of individuals with rare diseases."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph